Tumor Lysis Syndrome (TLS) — Management Pathway
Cairo-Bishop laboratory/clinical classification; aggressive hydration, rasburicase for hyperuricemia, manage electrolytes and dialyze as needed.
TLS → rescue: 1) Aggressive IV hydration, maintain high urine output. 2) Hyperuricemia → rasburicase 0.05–0.2 mg/kg IV (urate oxidase; contraindicated in…
Step-by-step decision
Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.
🎓 Want to practice? Do a case challenge with this pathway → (get a case, choose management step by step, scored).
Full pathway
- [Decision] Cairo-Bishop classificationCairo-Bishop classification (laboratory/clinical TLS or high-risk)? (Most common after chemotherapy of high-burden hematologic malignancies (day 3 before to day 7 after). Laboratory TLS = ≥2 abnormalities or a 25% change from baseline: uric acid ≥476 µmol/L (8 mg/dL), potassium ≥6.0 mmol/L, phosphate ≥1.45 mmol/L (adults), calcium ≤1.75 mmol/L. Clinical TLS = laboratory TLS + one of: creatinine ≥1.5× ULN (AKI), arrhythmia/sudden death, seizure.)
- Laboratory/clinical TLS → TLS → rescue
- High-risk only, not yet TLS → High-risk prevention
- [End] High-risk preventionAggressive IV hydration to maintain urine output; allopurinol (xanthine oxidase inhibitor, prevents new uric acid only); monitor electrolytes, uric acid and renal function closely (every 4–6 h after chemotherapy). Routine urine alkalinization is no longer recommended.
- [End] TLS → rescue1) Aggressive IV hydration, maintain high urine output. 2) Hyperuricemia → rasburicase 0.05–0.2 mg/kg IV (urate oxidase; contraindicated in G6PD deficiency). 3) Hyperkalemia → manage as hyperkalemia (most life-threatening). 4) Hyperphosphatemia → phosphate binders, avoid calcium (unless symptomatic hypocalcemia, to prevent calcium-phosphate deposition). 5) Hypocalcemia → replace calcium only if symptomatic, do not over-correct. 6) Refractory hyperkalemia/hyperphosphatemia, oliguric renal failure, fluid overload → renal replacement therapy (dialysis). Recheck electrolytes frequently.
Source guidelines & references
- Cairo MS, Bishop M. Tumour lysis syndrome classification. Br J Haematol 2004; Coiffier/Howard TLS management consensus
This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.